SCHEMBL432229

SCHEMBL432229

O=C(O)c1ccccc1NC(=O)C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK2 O95069 1/20 0.55
KCNK10 P57789 1/20 0.55
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
PKM P14618 1/20 0.53
GRIK1 P39086 1/20 0.52
MASP2 O00187 1/20 0.51
DHODH Q02127 1/20 0.51
PDK1 Q15118 2/20 0.51
PDK2 Q15119 2/20 0.51
PDK3 Q15120 2/20 0.51
PDK4 Q16654 2/20 0.51
TRPA1 O75762 1/20 0.51
TRPM8 Q7Z2W7 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
TP53 P04637 2/20 0.50
CA12 O43570 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716884 0.85 PDK1 (0.51) KCNK2KCNK10KMT2AMEN1PDK1
SCHEMBL29118239 0.84 ALDH1A1 (0.58) KCNK2KCNK10KMT2AMEN1PKM
SCHEMBL943096 0.84 PDK1 (0.71) PDK1PDK2PDK3PDK4TP53
SCHEMBL3591716 0.84 PDK1 (0.50) KMT2AMEN1PDK1PDK2PDK3
SCHEMBL8645992 0.84 KDM4E (0.55) KMT2AMEN1PKMPDK1PDK2
SCHEMBL9478517 0.84 PDK1 (0.50) KCNK2KCNK10KMT2AMEN1PDK1
SCHEMBL3994998 0.81 CETP (0.59) KMT2AMEN1PKMMASP2DHODH
SCHEMBL27953738 0.81 KMT2A (0.63) KMT2APDK1PDK2PDK3PDK4
SCHEMBL8893663 0.80 PTPN1 (0.64) KMT2AMEN1PKMGRIK1NPC1
SCHEMBL9994315 0.80 PDK2 (0.50) KMT2APDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105837432-A Novel preparation method of 3,5-dichlorobenzoyl chloride 山东润博生物科技有限公司 2016-08-10 CN claimed
US-8809526-B2 Synthesis of cyclopentaquinazolines ONYX PHARMACEUTICALS, INC. (US) 2014-08-19 US claimed
US-20130211082-A1 Synthesis of Cyclopentaquinazolines ONYX PHARMACEUTICALS, INC. (US) 2013-08-15 US claimed
EP-2595966-A2 SYNTHESIS OF CYCLOPENTAQUINAZOLINES Onyx Pharmaceuticals, Inc. (US) 2013-05-29 EP claimed
WO-2012011939-A2 SYNTHESIS OF CYCLOPENTAQUINAZOLINES ONYX PHARMACEUTICALS, INC. (US) 2012-01-26 WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
EP-4626868-A1 3-PHENYLQUINAZOLINONES AS NOVEL ANTI-CANCER THERAPY Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2025-10-08 EP disclosed
WO-2024115673-A1 3-PHENYLQUINAZOLINONES AS NOVEL ANTI-CANCER THERAPY Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2024-06-06 WO disclosed
US-11508566-B2 Use of anthranilic acid derivative as matrix for MALDI mass spectrometry NATIONAL TAIWAN UNIVERSITY (TW) 2022-11-22 US disclosed
US-20210066060-A1 USE OF ANTHRANILIC ACID DERIVATIVE AS MATRIX FOR MALDI MASS SPECTROMETRY NATIONAL TAIWAN UNIVERSITY (TW) 2021-03-04 US disclosed
EP-2595966-B1 SYNTHESIS OF CYCLOPENTAQUINAZOLINES BTG INT LTD (GB) 2020-10-28 EP disclosed
US-10188754-B2 Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) THE JOHNS HOPKINS UNIVERSITY (US) 2019-01-29 US disclosed
US-5187173-A Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders STERLING WINTHROP INC. (US) 1993-02-16 US disclosed
US-5128339-A Emphysema, rheumatoid arthritis, pancreatitis STERLING WINTHROP INC. (US) 1992-07-07 US disclosed
EP-0483928-A1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use STERLING WINTHROP INC. (US) 1992-05-06 EP disclosed
EP-0471756-A4 SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF 1992-04-08 EP disclosed
EP-0471756-A1 SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF. STERLING WINTHROP INC (US) 1992-02-26 EP disclosed
WO-1990013549-A1 SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF STERLING WINTHROP INC. (US) 1990-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL KCNK2 4535/4885KCNK10 4519/4885KMT2A 3189/4885
US-11508566-B2 Use of anthranilic acid derivative as matrix for MALDI mass spectrometry ACMSD, ANTXR2, HAAO KCNK2 2202/4885KCNK10 2409/4885KMT2A 193/4885
US-20130211082-A1 Synthesis of Cyclopentaquinazolines GLUL, QPCT, ASNS KCNK2 3552/4885KCNK10 3069/4885KMT2A 1880/4885
US-10188754-B2 Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) GART, SLC43A1, AADAT KCNK2 3746/4885KCNK10 4230/4885KMT2A 904/4885
US-20210066060-A1 USE OF ANTHRANILIC ACID DERIVATIVE AS MATRIX FOR MALDI MASS SPECTROMETRY ACMSD, ANTXR2, HAAO KCNK2 2202/4885KCNK10 2409/4885KMT2A 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.